1. Schachter M . Moxonidine: a review of safety and tolerability after seven years of clinical experience. J Hypertens Suppl 1999; 17: S37–S39.
2. Ernsberger P, Damon TH, Graff LM, Schäfer SG, Christen MO . Moxonidine, a centrally acting antihypertensive agent, is a selective ligand for I1-imidazoline sites. J Pharmacol Exp Ther 1993; 264: 172–182.
3. Wiêcek A, Fliser D, Nowicki M, Ritz E . Effect of moxonidine on urinary electrolyte excretion and renal haemodynamics in man. Eur J Clin Pharmacol 1995; 48: 203–208.
4. Haenni A, Lithell H . Moxonidine improves insulin sensitivity in insulin-resistant hypertensives. J Hypertens Suppl 1999; 17: S29–S35.
5. Topal E, Cikim AS, Cikim K, Temel I, Ozdemir R . The effect of moxonidine on endothelial dysfunction in metabolic syndrome. Am J Cardiovasc Drugs 2006; 6: 343–348.